Adagio Therapeutics Raises $336 Million Series C for COVID-19 Treatment and Prevention

Washington, DC – May 20, 2021 – Cooley advised Adagio Therapeutics, a biotechnology company developing antibodies to broadly neutralize coronaviruses, on its $336 million Series C financing round. Partners Brooke Nussbaum and Ryan Sansom led the Cooley team advising Adagio.

RA Capital Management led the round, which included participation from Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners and PremjiInvest, as well as existing investors Fidelity Management & Research Company, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds. Adagio will use the new capital to support continued advancement of ADG20, its lead clinical candidate, which is being developed as a single agent for both the treatment and prevention of COVID-19, as well potential future coronaviruses.

“The COVID-19 pandemic continues to be a major health crisis worldwide, and even with emergency use authorizations for vaccines and antibody-based therapies, there remains a significant need for medications to treat and prevent COVID-19 infection,” Tillman Gerngross, co-founder and chief executive officer of Adagio, said in a news release. “With the support of this sophisticated group of investors, we are properly capitalized to continue our expedited development and ultimate commercialization of ADG20 to benefit the many people at risk of COVID-19 mortality.”

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. The company’s portfolio of antibodies has been optimized using Adimab’s antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection, manufacturability and affordability.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,200 lawyers across 17 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.